Morgan Stanley Keeps Their Hold Rating on Outset Medical (OM)

Morgan Stanley analyst Drew Ranieri maintained a Hold rating on Outset Medical (OMResearch Report) today and set a price target of $17.00. The company’s shares opened today at $15.81.

Ranieri covers the Healthcare sector, focusing on stocks such as Alphatec Holdings, Haemonetics, and Integra Lifesciences. According to TipRanks, Ranieri has an average return of -9.4% and a 28.77% success rate on recommended stocks.

Currently, the analyst consensus on Outset Medical is a Moderate Buy with an average price target of $23.33.

See today’s best-performing stocks on TipRanks >>

OM market cap is currently $550.6M and has a P/E ratio of -4.63.

Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Outset Medical Inc is a medical technology company. The company has developed a machine, Tablo, which reduces the cost and complexity of dialysis.

Read More on OM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More